Walleye Capital
ADMA icon

Walleye Capital’s ADMA Biologics ADMA Stock Holding History

Walleye Capital’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-27,158
Closed -$245K – 4680
2026
Q1 		$245K Buy
+27,158
New +$429K ﹤0.01% 3206
2024
Q4 		– Sell
-73,568
Closed -$1.47M – 4760
2024
Q3 		$1.47M Buy
73,568
+25,442
+53% +$396K ﹤0.01% 2251
2024
Q2 		$538K Buy
48,126
+30,564
+174% +$256K ﹤0.01% 3445
2024
Q1 		$116K Buy
+17,562
New +$96K ﹤0.01% 4313
2023
Q4 		– Sell
-926,745
Closed -$3.32M – 4879
2023
Q3 		$3.32M Buy
+926,745
New +$3.57M 0.01% 1341
2023
Q1 		– Sell
-44,323
Closed -$172K – 3874
2022
Q4 		$172K Buy
+44,323
New +$137K ﹤0.01% 2132

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Walleye Capital's ADMA Position: Q2 2026 in Review

Walleye Capital sold out of ADMA Biologics (ADMA) in Q2 2026, closing a stake of 27,158 shares — an estimated $245K sold.

Walleye Capital first reported a position in ADMA in Q4 2022 and held it in 6 quarters. The position peaked at $3.32M in Q3 2023. 322 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • Walleye Capital reported no remaining ADMA Biologics position as of Q2 2026 after selling out during the quarter.
  • Walleye Capital sold 27,158 ADMA Biologics shares in Q2 2026, an estimated $245K.
  • Walleye Capital first reported a position in ADMA Biologics in Q4 2022 and held it in 6 quarters.
  • Walleye Capital's ADMA Biologics position peaked at $3.32M in Q3 2023.
  • 322 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.